About Kanyos Bio
Kanyos Bio is a company based in Cambridge (United States) founded in 2015 was acquired by Anokion in September 2019. Kanyos Bio has raised $16.41 million across 1 funding round from investors including Astellas Pharma, Anokion and Versant Ventures. The company has 12 employees as of December 31, 2022. Kanyos Bio offers products and services including SynCeD, ACeD-it, ACeD, and MoveS-it. Kanyos Bio operates in a competitive market with competitors including BeiGene, Biogen, Moderna, UCB and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 12 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kanyos Bio Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.41 M (USD)
in 1 rounds
-
Latest Funding Round
$16.41 M (USD), Series A
Jun 12, 2015
-
Investors
Astellas Pharma
& 4 more
-
Employee Count
12
as on Dec 31, 2022
-
Acquired by
Anokion
(Sep 11, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kanyos Bio
Kanyos Bio offers a comprehensive portfolio of products and services, including SynCeD, ACeD-it, ACeD, and MoveS-it.
Platform for treating celiac disease through immune tolerance
Treatment targeting celiac disease with engineered antigens
Additional therapy for celiac disease management
Platform for multiple sclerosis treatment via immune modulation
People of Kanyos Bio
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Kanyos Bio
Kanyos Bio has successfully raised a total of $16.41M through 1 strategic funding round. The most recent funding activity was a Series A round of $16.41 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kanyos Bio
Kanyos Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Astellas Pharma, Anokion and Versant Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for Kanyos Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kanyos Bio
Investment portfolio details for Kanyos Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kanyos Bio
Detailed financials for Kanyos Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kanyos Bio Comparisons
Peer comparison for Kanyos Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kanyos Bio
Kanyos Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Biogen, Moderna, UCB and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
Detailed competitors of Kanyos Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kanyos Bio
Complete news archive for Kanyos Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kanyos Bio
Kanyos Bio was founded in 2015.
Kanyos Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Kanyos Bio is a funded company, having raised a total of $16.41M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Kanyos Bio is 12.
Kanyos Bio is developing antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease. Their technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland. The Hubbell lab at the EPFL developed a method to harness the tolerogenic potential of the erythrocyte by engineering proteins to bind to circulating erythrocytes after simple intravenous injection. So, as the erythrocytes undergo natural cell death and are processed by immune cells, their protein cargo (the engineered proteins) are tolerized as well. As an independent affiliate, Kanyos aims to develop antigen-specific, disease-modifying therapies for patients with type-1 diabetes and celiac disease by leveraging the immunotechnology expertise of Anokion and the clinical translation experience of Astellas.
Kanyos Bio's top competitors include Moderna, BeiGene and Serum Institute of India.
Kanyos Bio offers SynCeD, ACeD-it, ACeD, and MoveS-it.
Kanyos Bio has 5 investors. Key investors include Astellas Pharma, Anokion, Versant Ventures, Novartis Venture Fund, and Novo Holdings.